Gary Brecka

It created an antibody.

They re-infused that patient's own antibodies into their system, and it ate the cancer like a termite.

And I've watched this happen.

I'd be happy to give you the data.

And I look at the risk of taking a patient's own natural killer cells out of their body, introducing them in vitro to cancer, creating this immune response and then re-infusing those back into the body.

The risk of rejection is obviously very low.

It's their own natural killer.

and seeing in multiple cases that this was a miracle for these patients.

Those are the kinds of things I would love to see the FDA at least have an open eye to and say, look, we know that intra-articular stem cells have actually avoided joint replacements.

We know that they've accelerated wound healing.

We've actually accelerated...

the post-surgical timeframe to full recovery.

And there's a promising frontier here, but whether it's pharma or medical dogma that's standing in the way of a lot of these technologies that are being widely used outside the United States, blood filtration technologies,

biologic filters, plasma filtration, dendritic cell vaccine, natural killer cells.

I've seen these therapies work in front of my own eyes for people that are going outside of the country and having them done.

Are you saying that the FDA is open to looking at that data and helping potentially advance those therapies?

We have to be.

We have to use common sense.

I mean, if somebody...

And this is the case of this PD-1 inhibitor where the rectal cancers have shrunk to nothing, no detectable.